Back to top
more

Corbus Pharmaceuticals (CRBP)

(Delayed Data from NSDQ)

$56.66 USD

56.66
255,419

-2.41 (-4.08%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $55.92 -0.74 (-1.31%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (154 out of 251)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -25.00% and -83.57%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock?

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

Do Options Traders Know Something About Corbus Pharmaceuticals (CRBP) Stock We Don't?

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Corbus Pharmaceuticals (CRBP) Moves to Buy: Rationale Behind the Upgrade

Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sweta Killa headshot

Cannabis ETF Tops in January: 5 Stocks That Led the Way

Inside the top performing stocks in the top ETF of January.

Corbus Pharmaceuticals (CRBP) Catches Eye: Stock Jumps 7.3%

Corbus Pharmaceuticals (CRBP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Implied Volatility Surging for Corbus Pharmaceuticals (CRBP) Stock Options

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Corbus (CRBP) Stock?

Investors need to pay close attention to Corbus (CRBP) stock based on the movements in the options market lately.

Corbus Pharmaceuticals (CRBP) Reports Q3 Loss, Lags Revenue Estimates

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -4.88% and -64.01%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Aurora Cannabis (ACB) to Post Q1 Earnings: What's in Store?

Aurora Cannabis' (ACB) fiscal first-quarter results are likely to reflect solid prospects in the Canadian market.

Corbus Pharmaceuticals (CRBP) Expected to Beat Earnings Estimates: Should You Buy?

Corbus Pharmaceuticals (CRBP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Corbus Stock Down as Lenabasum Fails to Meet Primary Endpoint

Corbus (CRBP) releases disappointing top-line results from its 28-week phase IIb study of lenabasum in patients with cystic fibrosis.

Are Options Traders Betting on a Big Move in Corbus (CRBP) Stock?

Investors need to pay close attention to Corbus (CRBP) stock based on the movements in the options market lately.

Implied Volatility Surging for Corbus Pharmaceuticals (CRBP) Stock Options

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Corbus Pharmaceuticals (CRBP) Stock?

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Corbus Pharmaceuticals (CRBP) Stock?

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

Is Corbus Pharmaceuticals (CRBP) Stock a Solid Choice Right Now?

Corbus Pharmaceuticals (CRBP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Corbus Pharmaceuticals (CRBP) Moves to Buy: Rationale Behind the Upgrade

Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Do Options Traders Know Something About Corbus Pharmaceuticals (CRBP) Stock We Don't?

Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Tops Revenue Estimates

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 0.00% and 7.44%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Corbus (CRBP) Stock Options

Investors need to pay close attention to Corbus (CRBP) stock based on the movements in the options market lately.

Corbus Pharmaceuticals (CRBP) Reports Q4 Loss, Lags Revenue Estimates

Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -20.59% and -44.55%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?